<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16493">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717209</url>
  </required_header>
  <id_info>
    <org_study_id>25471</org_study_id>
    <nct_id>NCT01717209</nct_id>
  </id_info>
  <brief_title>Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement</brief_title>
  <official_title>Combined Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplantation and for Left Ventricular Assist Device Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research study evaluating the individual and combined effects of inhaled medications, nitric
      oxide and prostacyclin, on the function of the right heart after surgery for either heart
      transplant or for left ventricular assist device (LVAD) placement. The investigators hope to
      learn if these two medications, when given together after surgery, improve right heart
      function by lowering blood vessel pressures in the lungs. The investigators hope to learn if
      the combined effects of these two medications are better than either medication used alone.
      Participants were selected as a possible participant in this study because right heart
      problems are common during and after surgery for heart transplant and for LVAD placement. In
      addition, the inhaled medication, nitric oxide, is always given during and after these two
      types of surgeries at Stanford to help improve how the right heart functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will begin once the participant arrives in the CTICU after heart surgery for
      either heart transplant or LVAD placement. As is standard of care after these types of
      surgeries, the participant will arrive in the CTICU with a breathing tube already in place,
      receiving iNO, and connected to a breathing machine. The participant will be receiving
      relaxing medication in an intravenous line provided by the cardiac anesthesiologist and the
      CTICU physicians. The participant will be unaware of the study period while the participant
      is sedated.  Data will be collected from the monitor screen connected to the
      participant'sarterial and venous lines, and if placed, LVAD monitor. These data are:

      Central venous pressure (CVP) Mean arterial pressure (MAP) Mean pulmonary artery pressure
      (MPAP) Cardiac Index (CI) Systemic vascular resistance (SVR) Pulmonary vascular resistance
      (PVR) Right ventricular stroke work index (RVSWI) LVAD Flow LVAD Pulsatility Index (PI)

      These data will be collected at five different time periods during the first eight hours
      after surgery.

        1. Time zero. Data will be collected after surgery upon your arrival to the CTICU while
           receiving iNO.

        2. After two hours data will be collected. iPGI2 will then be combined with the current
           iNO.

        3. After two hours of combined iNO and iPGI2, data will be collected. iNO will then be
           stopped.

        4. Data will be collected after two hours of solo iPGI2 therapy. iNO will be restarted.

        5. After two hours of combined iNO and iPGI2, data will be collected. The study ends after
           this data collection time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pulmonary Hypertension</measure>
    <time_frame>Eight Hours after cardiac surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pulmonary hypertension is common during and after cardiac surgery for heart transplant and for LVAD placement. Pulmonary hypertension is a risk factor for right heart dysfunction after these types of surgeries while the patient is in the intensive care unit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right heart dysfunction</measure>
    <time_frame>Eight Hours after cardiac surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Right heart dysfunction is common after cardiac surgery for heart transplant and for LVAD placement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Combined nitric oxide and prostacyclin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined inhaled nitric oxide 20 ppm continuously and inhaled prostacyclin 0.05 micrograms/kg/min continuously for 2 hours duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>inhaled nitric oxide</description>
    <arm_group_label>Combined nitric oxide and prostacyclin</arm_group_label>
    <other_name>INOmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostacyclin</intervention_name>
    <description>inhaled prostacyclin</description>
    <arm_group_label>Combined nitric oxide and prostacyclin</arm_group_label>
    <other_name>inhaled flolan</other_name>
    <other_name>epoprostenol</other_name>
    <other_name>inhaled PGI2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult cardiac surgical patients scheduled to undergo either heart transplantation or
             left ventricular assist device (LVAD) placement

        Exclusion Criteria:

          -  Patients with prior documented allergic reactions or intolerance to either nitric
             oxide or prostacyclin will be excluded. Patients not undergoing heart transplantation
             or LVAD placement will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Powers, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Powers, MD</last_name>
    <phone>650-723-2300</phone>
    <email>apowers@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Hill, MD</last_name>
    <phone>(650) 725-1930</phone>
    <email>chill1@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J Powers, MD</last_name>
      <phone>734-751-5949</phone>
    </contact>
    <investigator>
      <last_name>Andrew J Powers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg. 2009 Dec;138(6):1417-24.</citation>
    <PMID>19931670</PMID>
  </results_reference>
  <results_reference>
    <citation>De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, Zanaboni PB, Moazami N, Smith JR. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004 Apr;127(4):1058-67.</citation>
    <PMID>15052203</PMID>
  </results_reference>
  <results_reference>
    <citation>Potapov E, Meyer D, Swaminathan M, Ramsay M, El Banayosy A, Diehl C, Veynovich B, Gregoric ID, Kukucka M, Gromann TW, Marczin N, Chittuluru K, Baldassarre JS, Zucker MJ, Hetzer R. Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. J Heart Lung Transplant. 2011 Aug;30(8):870-8. doi: 10.1016/j.healun.2011.03.005. Epub 2011 Apr 29.</citation>
    <PMID>21530317</PMID>
  </results_reference>
  <results_reference>
    <citation>Antoniou T, Prokakis C, Athanasopoulos G, Thanopoulos A, Rellia P, Zarkalis D, Kogerakis N, Koletsis EN, Bairaktaris A. Inhaled nitric oxide plus iloprost in the setting of post-left assist device right heart dysfunction. Ann Thorac Surg. 2012 Sep;94(3):792-8. doi: 10.1016/j.athoracsur.2012.04.046. Epub 2012 Jun 23.</citation>
    <PMID>22727248</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 29, 2012</lastchanged_date>
  <firstreceived_date>October 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrew J. Powers</investigator_full_name>
    <investigator_title>Cardiac Anesthesia Fellow</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>hypertension, pulmonary</keyword>
  <keyword>heart failure, right-sided</keyword>
  <keyword>heart-assist devices</keyword>
  <keyword>Heart Transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
